Ciclesonide/formoterol

Drug Profile

Ciclesonide/formoterol

Alternative Names: BY9010/M-1506; Ciclesonide/formoterol fumarate; Formoterol/ciclesonide

Latest Information Update: 23 Jun 2015

Price : $50

At a glance

  • Originator Nycomed
  • Developer Sunovion Pharmaceuticals; Takeda Pharmaceuticals International GmbH
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Pregnenediones; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Immunosuppressants; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 30 Sep 2011 Nycomed has been acquired by Takeda
  • 12 Oct 2010 Sepracor is now called Sunovion Pharmaceuticals
  • 20 Oct 2009 Sepracor has been acquired by Dainippon Sumitomo Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top